NeuroEM Therapeutics Announces Completion of Clinical Trial Testing Its Novel Head Device Against Alzheimer's Disease

Phoenix, AZ (January 8th, 2019) A ground-breaking clinical trial has just been completed that evaluated the safety and initial efficacy of a wearable head device to treat Alzheimer's Disease. The Phase I clinical trial involved daily in home treatment of Alzheimer's patients with Transcranial Electromagnetic Treatment (TEMT).

This first-of-its-kind clinical trial, sponsored by Phoenix-based NeuroEM Therapeutics, was conducted at the University of South Florida's Byrd Alzheimer's Institute in Tampa. Results of the two-month treatment study are anticipated to be made public by the company in early summer.

NeuroEM Therapeutics' pre-clinical studies in Alzheimer's mice consistently showed that TEMT can protect against or reverse their cognitive impairment. These cognitive benefits appear to occur because of direct actions of TEMT on the Alzheimer's Disease process itself. Not only are clumps of toxic proteins inside brain cells disaggregated by TEMT, but this novel bioengineering technology also increases energy production by Alzheimer's brain cells starved of energy.

"Since our pre-clinical studies indicated TEMT to be safe and provide consistent memory benefits to Alzheimer's mice, it was important to see if TEMT could stabilize or reverse the memory impairment of human Alzheimer's patients" said Dr. Gary Arendash, Founder and CEO of NeuroEM Therapeutics. "This was a landmark clinical study in being the first to treatment the entire human forebrain with electromagnetic waves and over an extended period of time".

Treatment was administered twice daily in home by each patient's caregiver, who positioned a head device (called the MemorEM 1000) on the patient's head and monitored the two 1-hour daily treatments. The MemorEM head device allows near complete mobility to perform daily activities during a treatment session. In home treatment was critical in allowing for 120 treatment sessions over the two month treatment period – something that is not practical if visits to a clinical or hospital were required.

Phase I clinical trials almost always focus on establishing safety of a therapeutic. However, NeuroEM's just-completed Phase I clinical trial involved multiple measures of efficacy in addition to those for safety. A comprehensive array of Alzheimer's endpoints, including not only memory assessment, but also Alzheimer's markers in cerebrospinal fluid (CSF) and blood, and brain imaging were evaluated. In the study, each subject's baseline measures before the 2-month treatment period were compared to the same measures immediately following treatment and even at two weeks after completion of treatment.

"Given the failure of well over 100 drugs to provide cognitive benefit to Alzheimer's patients in many clinical trials over the past 15 years, it is now important to evaluate other therapeutic interventions against this horrible disease" said Dr. Arendash. "Our unique bioengineering approach to Alzheimer's may provide the disease-modifying approach needed to not just slow down the disease's memory loss, but to stabilize or reverse it."

NeuroEM anticipates releasing the results of their Phase I clinical trial in AD patients early this summer to the general public. The nearly six million people with Alzheimer's Disease in the U.S. and their loved ones are certainly hoping for a breakthrough therapeutics soon.

About NeuroEM Therapeutics, Inc.

NeuroEM Therapeutics is a clinical stage medical device company focused on development of Transcranial Electromagnetic Treatment (TEMT) to treat neurodegenerative disorders such as Alzheimer's Disease, Traumatic Brain Injury, and Down's Syndrome. The company is headquartered in Phoenix, AZ and has attained research support from NIH, foundations, and angel investors. NeuroEM's head device (the MemorEM 1000) is a first-in-class medical device that provides full brain electromagnetic treatment in-home and with near complete mobility. For more information about NeuroEM Therapeutics, go to www.neuroem.com.

Forward-Looking Statements

This communication contains certain forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, which may include, but are not limited to, statements concerning the projections, financial condition, results of operations and businesses of NeuroEM Therapeutics, are based on management's current expectations and estimates and involve risks and uncertainties that could cause actual results or outcomes to differ materially from those contemplated by the forward-looking statements.